Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Yeung EK, Siriwardana A, Buizen L, Tang AHC, Jun M, Polkinghorne KR, Tang SCW, Kotwal S, Arnott C, Levin A, Jardine M, Lim SK, Jha V, Mahaffey KW, Perkovic V, Heerspink HJL, Neuen BL

Open source

DOI: 10.1093/ndt/gfag203
Published: 2026 Sep 4
Container: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ndt/gfag203,
  title = {Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.},
  author = {Yeung EK and Siriwardana A and Buizen L and Tang AHC and Jun M and Polkinghorne KR and Tang SCW and Kotwal S and Arnott C and Levin A and Jardine M and Lim SK and Jha V and Mahaffey KW and Perkovic V and Heerspink HJL and Neuen BL},
  year = {2026},
  journal = {Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  doi = {10.1093/ndt/gfag203},
  url = {https://doi.org/10.1093/ndt/gfag203}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.
AU  - Yeung EK
AU  - Siriwardana A
AU  - Buizen L
AU  - Tang AHC
AU  - Jun M
AU  - Polkinghorne KR
AU  - Tang SCW
AU  - Kotwal S
AU  - Arnott C
AU  - Levin A
AU  - Jardine M
AU  - Lim SK
AU  - Jha V
AU  - Mahaffey KW
AU  - Perkovic V
AU  - Heerspink HJL
AU  - Neuen BL
PY  - 2026
JO  - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
DO  - 10.1093/ndt/gfag203
UR  - https://doi.org/10.1093/ndt/gfag203
ER  -

APA

EK, Y., A, S., L, B., AHC, T., M, J., KR, P., SCW, T., S, K., C, A., A, L., M, J., SK, L., V, J., KW, M., V, P., HJL, H., & BL, N. (2026). Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. https://doi.org/10.1093/ndt/gfag203

Source records

pubmed · retrieved 2026-09-25T13:09:55.633Z